Le Lézard
Classified in: Health, Business
Subjects: LIC, AVO

AANA and APNA Issue Joint Statement on Ketamine Infusion Therapy for Psychiatric Disorders


ROSEMONT, Ill., Nov. 3, 2023 /PRNewswire/ -- The American Association of Nurse Anesthesiology (AANA) and the American Psychiatric Nurses Association (APNA) support a patient-centered, interdisciplinary approach to providing care and treatment to persons with psychiatric disorders who may benefit from ketamine infusion therapy. Ketamine infusion therapy has been shown to have antidepressive properties and is increasingly being used to treat psychiatric disorders, including major depressive disorder, bipolar disorder, treatment-resistant depression, and post-traumatic stress disorder.

Together, AANA and APNA have issued the following statement regarding ketamine infusion therapy for psychiatric disorders:

"The AANA and APNA recognize the expertise of certified registered nurse anesthetists (CRNAs), psychiatric-mental health registered nurses (PMH RNs), and psychiatric-mental health advanced registered nurses (PMH APRNs) who are educated and qualified to administer ketamine infusion therapy for psychiatric disorders in accordance with professional scope and standards of practice, federal and state law, and facility policy."

When administering ketamine for treatment of psychiatric disorders, CRNAs collaborate with psychiatric-mental health professionals whose practice includes diagnosing psychiatric disorders within their professional and state scope of practice.

As part of the collaboration, CRNAs obtain a referral or past medical records, including a psychiatric history, medication list, and diagnosis, prior to providing ketamine infusion therapy for psychiatric disorders.

"CRNAs are trained in delivering professional, compassionate anesthesia care and have the knowledge and training to deliver and monitor medications, such as ketamine.  This expertise makes them an ideal partner in the delivery of ketamine infusion therapy for psychiatric disorders," said AANA President Dru Riddle, PhD, DNP, CRNA, FAAN.

"Psychiatric-mental health (PMH) nurses are educated and clinically trained to offer evidence-based care and treatment to persons with mental health needs across the lifespan, including those who may benefit from ketamine infusion therapy. We are committed to interprofessional collaboration to provide the best possible care for those we serve," says APNA President Lora Peppard, PhD, DNP, PMHNP-BC," and we value the complementary expertise that CRNAs bring when working alongside PMH nurses in this area."

The CRNA's role in ketamine infusion therapy may include, but is not limited to, reviewing healthcare records; obtaining a health history; conducting a pre-infusion assessment and evaluation; ordering and evaluating diagnostic tests; ordering or prescribing medications; initiating, maintaining, titrating, and discontinuing the infusion; monitoring the patient; and conducting post-infusion assessment and evaluation.

PMH RNs and PMH APRNs specialize in promoting mental health through the assessment, diagnosis and treatment of behavioral problems, mental disorders, and co-morbid conditions. PMH APRNs work with patients who may benefit from ketamine infusion therapy by collecting and synthesizing health data and analyzing that data to determine diagnosis and areas of focus for care and treatment, as well as utilizing prescriptive authority, referrals, and procedures, treatments, and therapies in accordance with applicable law.

This collaboration exists to increase communication between the anesthesia and psychiatric-mental health professionals in order to create an optimal environment for safe care.  CRNAs and PMH nurses complement each other's skills and knowledge in the assessment, management, and delivery of ketamine infusion therapy for appropriate psychiatric disorders with a focus on improved patient safety, outcomes, and general well-being.

SOURCE American Association of Nurse Anesthesiology


These press releases may also interest you

at 18:05
Celltrion partners with TV star Mollie Pearce to launch the second installation of the Where's Crohn's & Colitis (CC)? campaign for this year's World IBD Day (19 May 2024). The campaign focuses on access to IBD care and treatment as the burden of...

at 14:06
On Wednesday, May 15, Red Door Community hosted their annual Celebrating Women Working and Living with Cancer Luncheon at the Metropolitan Club in New York City. The event raised more than $300,000 while shining a light on the women who inspire us...

at 14:05
Product: Kalihim (Philippine Bread Roll) Issue: Food - Allergen - Egg Distribution: British Columbia See the affected products and product photos for this recall SOURCE Canadian Food Inspection Agency (CFIA)

at 13:27
The global industrial automation market in life sciences industry  size is estimated to grow by USD 5.06 bn from 2024-2028, according to Technavio. The market is estimated to grow at a CAGR of  11.4%  during the forecast period. ...

at 11:03
Boston Scientific Corporation today announced positive six-month results from the ongoing pivotal MODULAR ATP clinical trial of the mCRMtm System,* the first modular cardiac rhythm management (CRM) system that consists of the EMBLEMtm Subcutaneous...

at 08:35
Gilead Sciences, Inc. , following the recent acquisition of CymaBay Therapeutics, Inc., today announced interim results from the ongoing ASSURE study demonstrating treatment with seladelpar, an investigational PPAR delta agonist, led to improvements...



News published on and distributed by: